One in ten British adults used or interested in GLP-1 medications for weight loss owenhaskins Jan 8 4 min read In 2025, approximately 4.9 million British adults almost one in ten are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss
Make adjustments to your diet such as including more Omega fatty acids since they can help reduce dryness
Dexcom G6 and G7 are Oscars preferred continuous glucose monitors (CGM) and are also available to members through prior authorization
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Bile acid dysregulationimpaired FXR/TGR5 signalingreduced enteroendocrine GLP-1 secretionattenuated postprandial insulin response
tightness in the chest or throat
